mAbs Against HUMAN Protein
LMO2
| STATUS: |  |
|---|---|
| CONTACT INFORMATION: | Monoclonal Antibodies Unit, Centro Nacional de Investigaciones Oncológicas |
| STATUS: | Validated |
| TYPE: | mouse anti human |
| CLONE NAME: | 229B |
| PROTEIN: | human full length LMO2 |
| PROTEIN WEB: | http://www.ncbi.nlm.nih.gov/protein/214832074 |
| ANTIGEN USED: | His-GST-LMO2 recombinant protein |
| FUSION PARTNER: | NS1/Ag4-1 (NS1) cells |
| ISOTYPE: | IgG1 |
| SPECIES REACTIVITY: | Human |
| PREPARATION AND STORAGE: | Aliquot and store at 4C. Do not freeze |
| APP RECOMMENDED: | IHQ-paraffin, IF, WB |
| APP NO RECOMMENDED: | IHQ-frozen |
| APP NO TESTED: | IP, Flow cytometry |
Description
LMO2 encodes a cysteine-rich, two LIM-domain protein that is required for yolk sac erythropoiesis. The LMO2 protein has a central and crucial role in hematopoietic development and is highly conserved. The LMO2 transcription start site is located approximately 25 kb downstream from the 11p13 T-cell translocation cluster (11p13 ttc), where a number T-cell acute lymphoblastic leukemia-specific translocations occur. Alternative splicing results in multiple transcript variants encoding different isoforms. LMO2 protein is expressed as a nuclear marker in normal germinal-center (GC) B cells and GC-derived B-cell lines and in a subset of GC-derived B-cell lymphomas. LMO2 is expressed in erythroid and myeloid precursors and in megakaryocytes and also in lymphoblastic and acute myeloid leukemias. It is rarely expressed in mature T, natural killer (NK), and plasma cell neoplasms and is absent from nonhematolymphoid tissues except for endothelial cells.
Applications
| IHC Techniques | Clone | Dilution | Antibody concentration | Antigen retrieval method | Visualization kit | +/- control | Protein localization | Positivity in other species | Protocol |
|---|---|---|---|---|---|---|---|---|---|
| Frozen tissue and cytospins | |||||||||
Recommended Result obtained is satisfactory. The reagent can be use in this application | 229B | 1:10 | supernatant | none | goat anti mouse DAKO | Tonsil / | nuclear | ||
| Paraffin tissue | |||||||||
Recommended Result obtained is satisfactory. The reagent can be use in this application | 229B | 1:20 | supernatant | 15 minutes ER2 (Tris-EDTA) | Novolink kit | Tonsil / | nuclear | Available | |
| Immunofluorescence | |||||||||
Recommended Result obtained is satisfactory. The reagent can be use in this application | 229B | 1:100 | supernatant | 1 hour | Tonsil / | nuclear | Available | ||
Enlarge image
- LMO2 antibody (229B) in transfected cells.
- Validation of anti-LMO2 (229B) monoclonal antibody in HEK-V5-LMO2. Anti-LMO2 (1A9-1) and anti-V5 antibodies were used as positive controls. HEK-V5-FGFR4 transfected cells was used as negative control.
Enlarge image
- Anti-LMO2 (229B) immunohistochemistry on tonsil (A and B) and bone marrow (C) paraffin sections
Enlarge image
- Expression of LMO2 protein by human lymphoid cells.
- LMO2 is presented in Red. DAPI (blue).
| WB Techniques | Clone | Dilution | Antibody concentration | +/- control | Expected MW | Observed Mw | Positivity in other species | Protocol |
|---|---|---|---|---|---|---|---|---|
| Western Blotting | ||||||||
Not recommended Reagent discarded for this application | 229B | 1:10 | supernatant | / | 16kDa | Available | ||
| Immunoprecipitation | ||||||||
Enlarge image
- Western blotting of anti-LMO2 using transfected cells and different lymphoma cell lines.
- Western blotting of anti-LMO2 using transfected cells and different lymphoma cell lines. Description: Anti-LMO2 antibody (229B). Lane 1 Hek-LMO2 transfected cells (20ug) (+) Lane 2 Hek-Bcl10 transfected cells (20ug) (-) Lane 3 SUDHL6 cell line (100ug) (+) Lane 4 OCILY19 cell line (100ug) (+) Lane 5 OCILY3 cell line (100ug) (-) Lane 6 Raji cell line (100ug) (-) Lane 7 Ramos cell line (100ug) (+) Lane 8 Hela cell line (100ug) (-) Tubulin was used as loading control.